OTCMKTS:OPNT
Delisted
Opiant Pharmaceuticals Inc. Stock News
$20.65
+0 (+0%)
At Close: May 26, 2023
Opiant Pharmaceuticals Announces First Quarter 2021 Financial Results and Corporate Update
04:05pm, Tuesday, 11'th May 2021
SANTA MONICA, Calif., May 11, 2021 (GLOBE NEWSWIRE) -- Opiant Pharmaceuticals, Inc. (“Opiant”) (NASDAQ: OPNT), a specialty pharmaceutical company developing medicines to treat addictions and drug
Opiant Pharmaceuticals Announces First Subjects Dosed in Study Comparing OPNT003, Nasal Nalmefene, With Nasal Naloxone
04:01pm, Monday, 05'th Apr 2021
SANTA MONICA, Calif., April 05, 2021 (GLOBE NEWSWIRE) -- Opiant Pharmaceuticals, Inc. (“Opiant”) (NASDAQ: OPNT), a specialty pharmaceutical company developing medicines to treat addictions and dr
SANTA MONICA, Calif., March 22, 2021 (GLOBE NEWSWIRE) -- Opiant Pharmaceuticals, Inc. (“Opiant”) (NASDAQ: OPNT), a specialty pharmaceutical company developing medicines to treat addictions and dr
Opiant Pharmaceuticals' (OPNT) CEO Roger Crystal on Q4 2020 Results - Earnings Call Transcript
08:53pm, Thursday, 04'th Mar 2021
Opiant Pharmaceuticals' (OPNT) CEO Roger Crystal on Q4 2020 Results - Earnings Call Transcript
Recap: Opiant Pharmaceuticals Q4 Earnings
04:48pm, Thursday, 04'th Mar 2021
Shares of Opiant Pharmaceuticals (NASDAQ:OPNT) were flat after the company reported Q4 results. Quarterly Results Earnings per share decreased 180.00% over the past year to ($0.16), which missed the e
Opiant Pharmaceuticals Reports Fourth Quarter and Full-Year 2020 Financial Results and Provides Corporate Update
04:05pm, Thursday, 04'th Mar 2021
SANTA MONICA, Calif., March 04, 2021 (GLOBE NEWSWIRE) -- Opiant Pharmaceuticals, Inc. (“Opiant”) (NASDAQ: OPNT), a specialty pharmaceutical company developing medicines to treat addictions and dr
Opiant Pharmaceuticals to Report Fourth Quarter 2020 Financial Results and Host Conference Call and Webcast on March 4, 2021
04:01pm, Monday, 22'nd Feb 2021
SANTA MONICA, Calif., Feb. 22, 2021 (GLOBE NEWSWIRE) -- Opiant Pharmaceuticals, Inc. (“Opiant”) (NASDAQ: OPNT), a specialty pharmaceutical company developing medicines for addictions and drug ove
SANTA MONICA, Calif., Feb. 08, 2021 (GLOBE NEWSWIRE) -- Opiant Pharmaceuticals, Inc. (“Opiant”) (NASDAQ: OPNT) today announced the dosing of the first patient in a confirmatory pharmacokinetic (�
SANTA MONICA, Calif., Dec. 14, 2020 (GLOBE NEWSWIRE) -- Opiant Pharmaceuticals, Inc. (“Opiant”) (NASDAQ: OPNT) today announced an additional commitment of up to $3.5 million from the Biomedical
Opiant Pharmaceuticals Secures $50 Million in Convertible Debt Financing
04:01pm, Thursday, 10'th Dec 2020
SANTA MONICA, Calif., Dec. 10, 2020 (GLOBE NEWSWIRE) -- Opiant Pharmaceuticals, Inc. (“Opiant”) (NASDAQ: OPNT), a specialty pharmaceutical company developing medicines to treat addictions and dru
Opiant Pharmaceuticals Announces Appointment of Biopharmaceutical Leader Craig A. Collard as Chairman to its Board of Directors
04:01pm, Monday, 07'th Dec 2020
SANTA MONICA, Calif., Dec. 07, 2020 (GLOBE NEWSWIRE) -- Opiant Pharmaceuticals, Inc. (“Opiant”) (NASDAQ: OPNT), a specialty pharmaceutical company developing medicines to treat addictions and dru
Where Do Hedge Funds Stand On Opiant Pharmaceuticals, Inc. (OPNT)?
09:58am, Friday, 27'th Nov 2020
In this article we will check out the progression of hedge fund sentiment towards Opiant Pharmaceuticals, Inc. (NASDAQ:OPNT) and determine whether it is a good investment right now. We at Insider Monk
Opiant Pharmaceuticals, Inc. (OPNT) CEO Roger Crystal on Q3 2020 Results - Earnings Call Transcript
08:06pm, Thursday, 12'th Nov 2020
Opiant Pharmaceuticals, Inc. (OPNT) CEO Roger Crystal on Q3 2020 Results - Earnings Call Transcript
Opiant Pharmaceuticals: Q3 Earnings Insights
04:41pm, Thursday, 12'th Nov 2020
Shares of Opiant Pharmaceuticals (NASDAQ:OPNT) were flat after the company reported Q3 results. Quarterly Results Earnings per share fell 92.39% over the past year to $0.15, which beat the estimate of
Opiant Pharmaceuticals Announces Third Quarter 2020 Financial Results and Corporate Update
04:05pm, Thursday, 12'th Nov 2020
SANTA MONICA, Calif., Nov. 12, 2020 (GLOBE NEWSWIRE) -- Opiant Pharmaceuticals, Inc. (“Opiant”) (NASDAQ: OPNT), a specialty pharmaceutical company developing medicines to treat addictions and dru
